AI start-up with platform that speeds up drug discovery scoops $1 million investment
Start-up iLoF (Intelligent Lab on Fiber), uses artificial intelligence (AI) and biophotonics to detect neurogenerative biomarkers and optimise the clinical trial selection process for diseases such as Alzheimer's.
iLoF also won the EIT Health Wild Card competition in 2019 and has secured $1 million in investment from Microsoft’s Venture Fund, M12 and Mayfield Fund.
Following the team’s entry into the EIT Health open innovation Wild Card programme in 2019, iLoF was formed and €2million in investment plus a mentoring package was provided to develop the company and solution. Honing in on the repeated clinical trial failures in neurogenerative diseases such as Alzheimer’s, the solution aims to improve the process of clinical trial screening and speed up drug discovery in diseases with little, or no, treatment options.
iLof has also attracted the attention of the biotech world, with its cofounders being named in the 2020 Forbes 30 under 30 Europe list in the science and healthcare category.1 Additionally, the team are finalists in the M12 Female Founders Competition.
“It is fantastic to see iLoF go from strength to strength following their formation as part of the EIT Health Wild Card programme”, said Jorge Juan Fernández García, Director of Innovation, EIT Health. “Wild Card was created to discover and develop highly talented individuals who can come together to form new companies that break ground in areas where solutions to challenges remain undiscovered. Effective treatments for neurodegenerative diseases are desperately needed yet continue to evade us - innovation in the research process to find new strategies in tackling such diseases will have significant impact, not to mention scientific value. We look forward to continuing working with iLoF and supporting them as they advance in their journey,” he added.
Challenges surrounding current clinical trial processes are significantly hindering the discovery of potential treatments in diseases such as Alzheimer’s, including difficulties in recruiting and retaining participants.3 iLoF’s solution uses biophotonics (the study of optical processes in biological systems allowing the imaging and sensing of cells and tissue) and AI to develop non-invasive methods of screening patients for clinical trials, and aims to accelerate the drug discovery process and make it more economically viable.
“This investment will be crucial to our mission of accelerating personalised treatments for patients all around the world”, said Luis Valente, CEO of iLoF. “Our platform technology is growing rapidly and is already being deployed with leading hospitals and biotechs around the globe, expediting the discovery and development of new therapeutics for neurogenerative diseases. By 2021, we aim to enrol a large-scale clinical trial as a precise, non-invasive pre-screening tool for Alzheimer’s, bringing us one step closer to our goal of making the patient’s journey much more humane and convenient, while drastically transforming the whole process into a more efficient and flexible experience for the industry.
Best Practice Approaches & Overcoming Potential Challenges in Targeting Kinases for Drug Discovery READ MORE
3D Cell Culture - A Rapidly Emerging Technique for Drug Discovery READ MORE
PrecisionLife identifies 68 genes associated with risk of severe COVID-19 READ MORE
Collaboration launches Autobahn Labs, novel early stage drug discovery incubator READ MORE
PharmEnable raises £1.8 million for drug discovery expansion READ MORE
ViiV Healthcare to present new HIV data at International AIDS Conference READ MORE
ELRIG announces Drug Discovery Digital READ MORE
How drug discovery software is inspiring US high-school students READ MORE
Cost-effective drug discovery: How this AI system aims to assist READ MORE